Open-House-Biologika-Rabattverträge 2025-15
Original notice title
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-15
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume guarantee; actual revenue depends on market uptake and prescribing behavior.
The contract terminates automatically at the end of the month in which patent or market exclusivity expires, potentiall...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Jul 2027
- Supply of Trastuzumab (subcutaneous injection) under a discount contract with German statutory health insurance funds.
- Conclusion of a framework-type agreement without volume commitment; no exclusivity for any contractor.
Show full summary
Open-House procedure by German health insurance funds (led by Techniker Krankenkasse) for discount contracts on Trastuzumab (subcutaneous injection). The procedure is open to all eligible pharmaceutical entrepreneurs throughout the contract term (max. 24 months, 01.08.2025 – 31.07.2027). No estimated contract value is provided; the procedure is not a public procurement subject to EU procurement law but a voluntary publication. Participation is possible at any time during the contract term, with specific deadlines for inclusion in the monthly pharmacy software update.
Risks
No estimated value or volume guarantee; actual revenue depends on market uptake and prescribing behavior.
The contract terminates automatically at the end of the month in which patent or market exclusivity expires, potentiall...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per § 4 Abs. 18 AMG for the specific drug.
- Must have a valid marketing authorization for Trastuzumab (subcutaneous injection) in Germany.
Eligibility
- Must provide a self-declaration confirming eligibility and reliability.
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open-House-Biologika-Rabattverträge 2025-15
Single lot covering discount contracts for Trastuzumab (subcutaneous injection). All eligible pharmaceutical entrepreneurs can conclude a contract under uniform conditions; no exclusivity is granted. The contract ends at the latest on 31.07.2027, or earlier upon patent expiry/market exclusivity loss.
Location
Duration
Category
Award Criteria
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Trastuzumab (Darreichungsform zur subkutanen Injektion) im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Trastuzumab (Darreichungsform zur subkutanen Injektion) im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 19 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 323734-2025
Documents (1)
Similar tenders
Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)
Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów
France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord
Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)
Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ
Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume guarantee; actual revenue depends on market uptake and prescribing behavior.
The contract terminates automatically at the end of the month in which patent or market exclusivity expires, potentiall...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications